Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Dec;7(Suppl 8):S355.
doi: 10.21037/atm.2019.09.56.

Non-selective beta blockers in cirrhosis: time to extend the indications?

Dev Katarey  1 , Rajiv Jalan  1
Affiliations
Editorial

Non-selective beta blockers in cirrhosis: time to extend the indications?

Dev Katarey et al. Ann Transl Med. 2019 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: R Jalan has served as a speaker, a consultant and an advisory board member for Sequana Medical, Yaqrit, Mallinckrodt, Organovo, Prometic, Takeda, has received research funding from Yaqrit, Takeda, owns stocks and shares in Yaqrit, Thoeris, Cyberlive and owns the patent Yaq-001; DIALIVE; Ornithine Phenylacetate; TLR4 antagonist. D Katarey has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
The effect of non-selective beta blockers on reducing bacterial translocation and thereby systemic inflammation, portal hypertension, and decompensation.
See this image and copyright information in PMC

Comment on

References

    1. Ginés P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987;7:122-8. 10.1002/hep.1840070124 - DOI - PubMed
    1. Villanueva C, Albillos A, Genescà J, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2019;393:1597-608. 10.1016/S0140-6736(18)31875-0 - DOI - PubMed
    1. Mookerjee RP, Pavesi M, Thomsen KL, et al. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. J Hepatol 2016;64:574-82. 10.1016/j.jhep.2015.10.018 - DOI - PubMed
    1. Mehta G, Gustot T, Mookerjee RP, et al. Inflammation and portal hypertension - the undiscovered country. J Hepatol 2014;61:155-63. 10.1016/j.jhep.2014.03.014 - DOI - PubMed
    1. Bernardi M, Moreau R, Angeli P, et al. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol 2015;63:1272-84. 10.1016/j.jhep.2015.07.004 - DOI - PubMed